Karyopharm: Ph1b/2 Selinexor (Multiple Myeloma) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if a study drug called selinexor (also known as XPOVIO) is a safe and effective treatment for multiple myeloma when it is combined with other drugs.

What is the Condition Being Studied?

Relapsed/Refractory and Newly Diagnosed Multiple Myeloma

Who Can Participate in the Study?

Adults ages 18+ who:
- Have multiple myeloma that is not responding to therapy; OR
- Have multiple myeloma that has come back after previous therapy; OR
- Are diagnosed with multiple myeloma and have not started therapy yet

For more information about who can join this study, please contact the study team 919-668-0613.

Age Group

What is Involved?

If you choose to join this study, you will take the study drug in combination with another drug called dexamethasone. In addition to these two drugs, you will be randomly assigned to take another drug or drug combination at the same time. The drugs you might take in addition to the study drug and dexamethasone are:
- pomalidomide; OR
- bortezomib; OR
- lenalidomide; OR
- daratumumab ; OR
- carfilzomib; OR
- ixazomib; OR
- pomalidomide and elotuzumab, ; OR
- belantamab mafodotin; OR
- pomalidomide and daratumumab.

The period in which you will take the study drug regimen consists of blocks of time called cycles. The number of study drug regimen cycles you take will depend on how you feel and how your cancer responds.

Study Details

Full Title
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Relapsed/Refractory Multiple Myeloma
Principal Investigator
Cellular Therapy Specialist
Protocol Number
IRB: PRO00069273
NCT: NCT02343042
Phase I/II
Enrollment Status
Open for Enrollment
Contact the Duke Recruitment Innovation Center